Cited by 246Bariatric Surgery and OutcomesDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Effects of diet versus gastric bypass on metabolic function in diabetes

Open access
Yoshino, Mihoko, Kayser, Brandon D., Yoshino, Jun, Stein, Richard I., Reeds, Dominic, Eagon, J. Christopher, Eckhouse, Shaina R., Watrous, Jeramie D. +5 more·2020·New England Journal of Medicine

Abstract

BACKGROUND: Some studies have suggested that in people with type 2 diabetes, Roux-en-Y gastric bypass has therapeutic effects on metabolic function that are independent of weight loss. METHODS: We evaluated metabolic regulators of glucose homeostasis before and after matched (approximately 18%) weight loss induced by gastric bypass (surgery group) or diet alone (diet group) in 22 patients with obesity and diabetes. The primary outcome was the change in hepatic insulin sensitivity, assessed by infusion of insulin at low rates (stages 1 and 2 of a 3-stage hyperinsulinemic euglycemic pancreatic clamp). Secondary outcomes were changes in muscle insulin sensitivity, beta-cell function, and 24-hour plasma glucose and insulin profiles. RESULTS: Weight loss was associated with increases in mean suppression of glucose production from baseline, by 7.04 μmol per kilogram of fat-free mass per minute (95% confidence interval [CI], 4.74 to 9.33) in the diet group and by 7.02 μmol per kilogram of fat-free mass per minute (95% CI, 3.21 to 10.84) in the surgery group during clamp stage 1, and by 5.39 (95% CI, 2.44 to 8.34) and 5.37 (95% CI, 2.41 to 8.33) μmol per kilogram of fat-free mass per minute in the two groups, respectively, during clamp stage 2; there were no significant differences between the groups. Weight loss was associated with increased insulin-stimulated glucose disposal, from 30.5±15.9 to 61.6±13.0 μmol per kilogram of fat-free mass per minute in the diet group and from 29.4±12.6 to 54.5±10.4 μmol per kilogram of fat-free mass per minute in the surgery group; there was no significant difference between the groups. Weight loss increased beta-cell function (insulin secretion relative to insulin sensitivity) by 1.83 units (95% CI, 1.22 to 2.44) in the diet group and by 1.11 units (95% CI, 0.08 to 2.15) in the surgery group, with no significant difference between the groups, and it decreased the areas under the curve for 24-hour plasma glucose and insulin levels in both groups, with no significant difference between the groups. No major complications occurred in either group. CONCLUSIONS: In this study involving patients with obesity and type 2 diabetes, the metabolic benefits of gastric bypass surgery and diet were similar and were apparently related to weight loss itself, with no evident clinically important effects independent of weight loss. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT02207777.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2003697

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Caloric restriction can rapidly reduce steatosis and hepatic insulin resistance.

    “Caloric restriction can rapidly reduce steatosis and hepatic insulin resistance [41][42][43].”

    From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [43]

    The Results (Multiorgan Insulin Sensitivity and Beta-Cell Function; page unavailable) report improved hepatic insulin sensitivity after diet-induced weight loss in people with obesity and type 2 diabetes. The paper does not report a reduction in steatosis or establish that the improvement occurred rapidly; the Methods (Weight-Loss Interventions; page unavailable) say participants maintained a stable weight for three weeks before repeat testing. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • In people with type 2 diabetes, weight loss after bariatric surgery elicited no additional differences in hepatic or whole-body insulin sensitivity compared to a control diet with comparable calorie intake, suggesting that the reduction of body fat mass is the major contributing factor to the observed metabolic benefits.

    “In people with type 2 diabetes, weight loss after bariatric surgery elicited no additional differences in hepatic or whole-body insulin sensitivity compared to a control diet with comparable calorie intake, suggesting that the reduction of body fat mass is the major contributing factor to the observed metabolic benefits [43].”

    From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [43]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Recent interventions with intensive diet and exercise, newer pharmacological agents, or surgical weight loss have led to diabetes remission.

    “Recent interventions with intensive diet and exercise, newer pharmacological agents (e.g., glucagon-like peptide 1 receptor agonists), or surgical weight loss have led to diabetes remission (86 -92)”

    From 2. Diagnosis and Classification of Diabetes: <i>Standards of Care in Diabetes—2024</i> (2024) · cites this paper as [91]

    The introduction (in the section labeled Abstract > Conclusions; page unavailable) reports a higher incidence of diabetes remission after gastric bypass than after certain other procedures. The Discussion reports improved metabolic function after diet or surgery, but not remission after intensive diet and exercise. The Methods mention GLP-1 receptor agonists only as medications discontinued before testing, not as a remission intervention. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yoshino, M., Kayser, B. D., Yoshino, J., Stein, R. I., Reeds, D., Eagon, J. C., Eckhouse, S. R., Watrous, J. D., Jain, M., Knight, R., Schechtman, K., Patterson, B. W., & Klein, S.
Affiliations
Washington University in St. Louis (US)
Venue
New England Journal of Medicine
Published
2020-08-20
Volume
383
Issue
8
Pages
721-732
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3057164079
Cited by
246
References
47
Citations by year
2026: 15 · 2025: 29 · 2024: 28 · 2023: 41 · 2022: 59 · 2021: 57 · 2020: 17
FWCI
39.73
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Heart, Lung, and Blood Institute (T32HL130357)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K01DK116917, P30DK063491, P30DK56341, R01DK101578, T32DK007296, U24DK097153)
  • NIH Office of the Director (S10OD020025)
  • National Institute of Environmental Health Sciences (P42ES010337, R01ES027595)
  • Pershing Square Foundation
  • Foundation for Barnes-Jewish Hospital
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 2 diabetes, Roux-en-Y gastric bypass, bariatric surgery, weight loss, dietary therapy, hepatic insulin sensitivity, skeletal muscle insulin sensitivity, beta-cell function, glucose homeostasis, glucose production, insulin-stimulated glucose disposal, obesity, hyperinsulinemic-euglycemic clamp, insulin secretion
MeSH terms
Adult, Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Obesity, Prospective Studies, Remission Induction, Glucose Clamp Technique, Gastric Bypass, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review